Skip to main content
. 2021 Aug 20;12(9):1421–1426. doi: 10.1021/acsmedchemlett.1c00216

Table 2. In Vitro DMPK Data of Pyrazolopyrimidine Analoguesa.

  LogD7.4 Aq. Sol. (μM) H. Mics. CL.(μL/min/mg) R. Hep. CL (μL/min/106 cells) H. PPB (%)
1 4.2 0.07 63.22 105.60 99.9
2 4.0 0.40 ND 59.03 99.80
3 4.3 0.90 49.19 67.66 99.8
10a 4.3 0.30 24.49 75.43 ND
10b 3.3 0.50 48.86 41.25 99.0
10c 3.7 0.01 8.76 46.48 99.7
10d 2.0 561 261.80 109.60 77.0
15a 4.0 0.60 83.97 113.20 99.9
15b 4.1 1.00 59.33 86.16 99.9
15c 4.5 5.00 8.76 156.60 97.9
15d 2.3 11.0 74.15 >300.00 88.0
15e 3.0 2.00 12.08 147.80 96.6
15f 3.3 2.00 21.78 27.58 99.8
15g 2.7 43.0 44.83 10.31 91.8
15h 2.3 30.0 243.60 144.90 97.4
15i 4.3 2.0 44.62 26.37 99.5
15j 2.4 21.0 23.65 71.84 ND
15k 4.0 6.0 37.48 45.53 99.6
a

Notes: Aq. Sol. = aqueous solubility in pH7.4 PBS; H. Mics. CL = intrinsic human microsomal clearance measured in vitro; R. Hep. CL = intrinsic Rat hepatocyte clearance measured in vitro; ND = not determined.